BIOMAT Database Logo BIOMAT Database Logo

A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments. 1979

M Bigazzi, and R Ronga, and I Lancranjan, and S Ferraro, and F Branconi, and P Buzzoni, and G Martorana, and G F Scarselli, and E Del Pozo

An unexpected 20-week-old pregnancy was found in a young acromegalic who had been treated with 10 mg bromocriptine/day for 10 months. The drug was continued throughout the period of gestation. No growth of the pituitary adenoma was noticed. The intrauterine development of the fetus was normal. Bromocriptine therapy had no discernible effect on the expected patterns of secretion of placental hormones, but inhibited completely the increase of PRL in the serum of the mother. Maternal plasma GH concentrations were very high in spite of the treatment and progressively declined after delivery. The plasma GH level was normal in the child, but PRL was very low at birth and increased in the following days. The expected high PRL concentration was found in the amniotic fluid. This case study suggests that bromocriptine crosses the human placenta and affects the fetal pituitary, maternal GH does not influence fetal or amniotic GH, and amniotic fluid PRL correlates poorly with either maternal or fetal blood levels and is not affected by bromocriptine.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008431 Maternal-Fetal Exchange Exchange of substances between the maternal blood and the fetal blood at the PLACENTA via PLACENTAL CIRCULATION. The placental barrier excludes microbial or viral transmission. Transplacental Exposure,Exchange, Maternal-Fetal,Exposure, Transplacental,Maternal Fetal Exchange
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011248 Pregnancy Complications Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases. Adverse Birth Outcomes,Complications, Pregnancy,Adverse Birth Outcome,Birth Outcome, Adverse,Complication, Pregnancy,Outcome, Adverse Birth,Pregnancy Complication
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D005312 Fetal Blood Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery. Cord Blood,Umbilical Cord Blood,Blood, Cord,Blood, Fetal,Blood, Umbilical Cord,Bloods, Cord,Bloods, Fetal,Bloods, Umbilical Cord,Cord Blood, Umbilical,Cord Bloods,Cord Bloods, Umbilical,Fetal Bloods,Umbilical Cord Bloods
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Bigazzi, and R Ronga, and I Lancranjan, and S Ferraro, and F Branconi, and P Buzzoni, and G Martorana, and G F Scarselli, and E Del Pozo
[Concentrations of growth hormone, prolactin and thyroid-stimulating hormone in the maternal, fetal and amniotic compartments].
February 1986, Nihon Sanka Fujinka Gakkai zasshi,
M Bigazzi, and R Ronga, and I Lancranjan, and S Ferraro, and F Branconi, and P Buzzoni, and G Martorana, and G F Scarselli, and E Del Pozo
Prolactin-releasing system in maternal, fetal, and amniotic compartments during labor.
July 1986, Obstetrics and gynecology,
M Bigazzi, and R Ronga, and I Lancranjan, and S Ferraro, and F Branconi, and P Buzzoni, and G Martorana, and G F Scarselli, and E Del Pozo
Growth hormone treatment during pregnancy in a growth hormone-deficient woman.
June 1995, European journal of endocrinology,
M Bigazzi, and R Ronga, and I Lancranjan, and S Ferraro, and F Branconi, and P Buzzoni, and G Martorana, and G F Scarselli, and E Del Pozo
[Growth hormone and prolactin in maternal plasma and amniotic fluid during normal gestation].
January 2005, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,
M Bigazzi, and R Ronga, and I Lancranjan, and S Ferraro, and F Branconi, and P Buzzoni, and G Martorana, and G F Scarselli, and E Del Pozo
Triplet pregnancy after pulsatile gonadotrophin-releasing hormone treatment in an acromegalic woman.
April 1994, European journal of obstetrics, gynecology, and reproductive biology,
M Bigazzi, and R Ronga, and I Lancranjan, and S Ferraro, and F Branconi, and P Buzzoni, and G Martorana, and G F Scarselli, and E Del Pozo
Benserazide effects on growth hormone, prolactin, and thyrotropin in normal and acromegalic man.
August 1985, The Journal of clinical endocrinology and metabolism,
M Bigazzi, and R Ronga, and I Lancranjan, and S Ferraro, and F Branconi, and P Buzzoni, and G Martorana, and G F Scarselli, and E Del Pozo
Bromocriptine-induced pregnancy in an acromegalic patient.
August 1980, JAMA,
M Bigazzi, and R Ronga, and I Lancranjan, and S Ferraro, and F Branconi, and P Buzzoni, and G Martorana, and G F Scarselli, and E Del Pozo
Pregnancy in an acromegalic after bromocriptine therapy.
July 1980, Irish journal of medical science,
M Bigazzi, and R Ronga, and I Lancranjan, and S Ferraro, and F Branconi, and P Buzzoni, and G Martorana, and G F Scarselli, and E Del Pozo
Prolactin in normal pregnancy: relationship of maternal, fetal, and amniotic fluid levels.
December 1975, American journal of obstetrics and gynecology,
M Bigazzi, and R Ronga, and I Lancranjan, and S Ferraro, and F Branconi, and P Buzzoni, and G Martorana, and G F Scarselli, and E Del Pozo
Growth hormone, insulin, and prolactin secretion in anorexia nervosa and obesity during bromocriptine treatment.
July 1977, British medical journal,
Copied contents to your clipboard!